• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Stabilizing Stable Coronary Artery Disease: No Beta-Blocker, No Problem?

作者信息

Chi Kuan-Yu, Nanna Michael G

机构信息

Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.

Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

出版信息

JACC Adv. 2025 Feb;4(2):101569. doi: 10.1016/j.jacadv.2024.101569. Epub 2025 Jan 17.

DOI:10.1016/j.jacadv.2024.101569
PMID:39826439
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11787414/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a29/11787414/e14ede96a616/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a29/11787414/e14ede96a616/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a29/11787414/e14ede96a616/ga1.jpg

相似文献

1
Stabilizing Stable Coronary Artery Disease: No Beta-Blocker, No Problem?稳定型冠状动脉疾病的稳定治疗：不用β受体阻滞剂，没问题？
JACC Adv. 2025 Feb;4(2):101569. doi: 10.1016/j.jacadv.2024.101569. Epub 2025 Jan 17.
2
Long-Term Beta-Blocker Therapy in Patients With Stable Coronary Artery Disease After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后稳定型冠状动脉疾病患者的长期β受体阻滞剂治疗
Front Cardiovasc Med. 2022 May 17;9:878003. doi: 10.3389/fcvm.2022.878003. eCollection 2022.
3
[Clinical outcomes with beta-blockers in stable patients undergoing percutaneous coronary intervention with adequate left ventricular ejection function].[β受体阻滞剂用于左心室射血功能正常的稳定型患者经皮冠状动脉介入治疗的临床结局]
Zhonghua Yi Xue Za Zhi. 2018 Dec 4;98(45):3666-3671. doi: 10.3760/cma.j.issn.0376-2491.2018.45.007.
4
Long-term impact of β-blocker in elderly patients without myocardial infarction after percutaneous coronary intervention.β受体阻滞剂对行经皮冠状动脉介入治疗的老年非心肌梗死患者的长期影响。
ESC Heart Fail. 2022 Feb;9(1):545-554. doi: 10.1002/ehf2.13715. Epub 2021 Nov 22.
5
Effect of Pre-Procedural Beta-Blocker on Clinical Outcome after Percutaneous Coronary Intervention in Acute Coronary Syndrome.术前使用β受体阻滞剂对急性冠状动脉综合征患者经皮冠状动脉介入治疗后临床结局的影响
Int Heart J. 2019 Nov 30;60(6):1284-1292. doi: 10.1536/ihj.19-175. Epub 2019 Nov 15.
6
Relationship Between β-Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.β受体阻滞剂出院后治疗与行经皮冠状动脉介入治疗的急性冠状动脉综合征患者临床结局的关系。
J Am Heart Assoc. 2016 Nov 16;5(11):e004190. doi: 10.1161/JAHA.116.004190.
7
Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.培哚普利与β受体阻滞剂预防稳定型冠状动脉疾病患者心脏事件及死亡：培哚普利降低稳定型冠状动脉疾病心脏事件的欧洲试验（EUROPA）亚组分析
Am Heart J. 2015 Dec;170(6):1092-8. doi: 10.1016/j.ahj.2015.08.018. Epub 2015 Aug 28.
8
β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.β受体阻滞剂在经皮冠状动脉介入治疗后的患者中的应用：一概而论？无心肌梗死或心力衰竭的患者结局更差。
Int J Cardiol. 2013 Sep 30;168(2):774-9. doi: 10.1016/j.ijcard.2012.10.001. Epub 2012 Nov 2.
9
Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results.β受体阻滞剂治疗经皮血运重建术治疗的冠心病患者降低死亡率：调整结果的荟萃分析。
J Cardiovasc Med (Hagerstown). 2018 Jul;19(7):337-343. doi: 10.2459/JCM.0000000000000662.
10
The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention.β受体阻滞剂治疗对经皮冠状动脉介入治疗后慢性冠状动脉疾病患者的临床影响。
Korean Circ J. 2022 Jul;52(7):544-555. doi: 10.4070/kcj.2021.0395. Epub 2022 Apr 4.

本文引用的文献

1
Beta-Blockers After PCI for Stable Coronary Artery Disease and Preserved Left Ventricular Ejection Fraction.经皮冠状动脉介入治疗后用于稳定型冠状动脉疾病及左心室射血分数保留患者的β受体阻滞剂
JACC Adv. 2025 Feb;4(2):101566. doi: 10.1016/j.jacadv.2024.101566. Epub 2025 Jan 17.
2
Beta-Blockers for Secondary Prevention following Myocardial Infarction in Patients Without Reduced Ejection Fraction or Heart Failure: An Updated Meta-Analysis.射血分数未降低或无心力衰竭的心肌梗死患者二级预防用β受体阻滞剂：一项更新的荟萃分析。
Eur J Prev Cardiol. 2024 Sep 20. doi: 10.1093/eurjpc/zwae298.
3
Beta-Blocker Interruption or Continuation after Myocardial Infarction.
心肌梗死后β受体阻滞剂的中断或继续。
N Engl J Med. 2024 Oct 10;391(14):1277-1286. doi: 10.1056/NEJMoa2404204. Epub 2024 Aug 30.
4
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.心肌梗死后射血分数保留的β受体阻滞剂
N Engl J Med. 2024 Apr 18;390(15):1372-1381. doi: 10.1056/NEJMoa2401479. Epub 2024 Apr 7.
5
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠状动脉疾病患者管理指南：美国心脏协会/美国心脏病学会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2023 Aug 29;82(9):833-955. doi: 10.1016/j.jacc.2023.04.003. Epub 2023 Jul 20.
6
Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction.β受体阻滞剂在射血分数轻度降低和保留的心衰患者中的应用与心衰结局的关系。
JACC Heart Fail. 2023 Aug;11(8 Pt 1):893-900. doi: 10.1016/j.jchf.2023.03.017. Epub 2023 May 3.
7
Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association.急性住院期间发生的心房颤动：美国心脏协会科学声明
Circulation. 2023 Apr 11;147(15):e676-e698. doi: 10.1161/CIR.0000000000001133. Epub 2023 Mar 13.
8
Association of Statin Use and Mortality After Transcatheter Aortic Valve Replacement.他汀类药物的使用与经导管主动脉瓣置换术后死亡率的关系。
J Am Heart Assoc. 2019 Apr 16;8(8):e011529. doi: 10.1161/JAHA.118.011529.
9
beta Blockade after myocardial infarction: systematic review and meta regression analysis.心肌梗死后的β受体阻滞剂治疗：系统评价与Meta回归分析
BMJ. 1999 Jun 26;318(7200):1730-7. doi: 10.1136/bmj.318.7200.1730.